s

Senzime’s rights issue oversubscribed

The Rights Issue was carried out in accordance with the decision made at the extraordinary general meeting on 3 March, 2017 and which involved the adoption of the Board's proposal for a new Rights Issue of 4,521,581 shares with pre-emption rights for existing shareholders. The subscription price was SEK 5.40 per share and the subscription period took place from 14 March 2017 to 28 March 2017.

The final count shows that 3 485 782 shares, corresponding to approximately 77,1 percent of the offered shares, were subscribed for with subscription rights. 1 172 712 shares, corresponding to approximately 25,9 percent of the offered shares, were subscribed for without subscription rights. The Rights Issue was subscribed to approximately 103 percent, representing an oversubscription ratio of about 3 percent. The company will raise approximately SEK 24.4 million before issue costs.

As notification of the allotment of new shares which have been subscribed for without subscription rights, a settlement note will be distributed to subscribers or nominees. Subscribed and allotted new shares shall be paid in cash on the settlement day in accordance with the instructions on the settlement note, around 6 April, 2017. Nominee registered shareholders will receive notification regarding allotment of shares in accordance with the respective nominee’s procedures.

New shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office on or about 10 April, 2017. When the Rights Issue has been fully registered, the paid subscribed shares will be converted into shares. The new shares are expected to be traded during the week 16 of 2017.

As a result of the Rights Issue, Senzime’s share capital will increase by SEK 502,397.88. The number of shares will increase in total by 4,521,581 shares, which means that the total number of shares and votes in the company after the Rights Issue will amount to 40,694,224.

"Now Senzime takes another big step towards the market. We have begun the commercialization of our product portfolio and aim to build a world-leading company in the perioperative patient monitoring. In recent months, we have signed agreements for the Japanese market, Australia, New Zeeland, Ireland and England. We expect several CE mark approvals followed by a broad market introduction in 2017. Growth capital will create conditions to accelerate the global commercialization of our product portfolio," says Lena Söderström, CEO of Senzime.

Advisor

Redeye AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser to Senzime in connection with the Rights Issue. Aqurat FK AB is the issuing institution in the Rights Issue.

Uppsala den  2017 Uppsala 3 April, 2017

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on April 3, 2017.